NEW YORK--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced the grant of inducement
awards to 14 employees that occurred on January 5, 2015. The awards were
granted as an inducement material to each such employee's entering into
employment with Retrophin pursuant to Rule 5635(c)(4) of the NASDAQ
Listing Rules. The 14 employees were granted inducement awards
consisting of stock options to purchase an aggregate of 355,000 shares
of Retrophin common stock and 40,000 shares of restricted common stock.
The stock options and restricted common stock vest in equal quarterly
installments over a period of three years. The stock options are
nonstatutory stock options and have an exercise price equal to $13.02
per share, the fair market value of Retrophin's common stock on the date
of grant.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's approved products include Chenodal®,
Thiola® and Vecamyl®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
schizophrenia, infantile spasms, nephrotic syndrome and others. For
additional information, please visit www.retrophin.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Without limiting the foregoing, these
statements are often identified by the words "may", "might", "believes",
"thinks", "anticipates", "plans", "expects", "intends" or similar
expressions. No forward-looking statement can be guaranteed. You are
cautioned not to place undue reliance on these forward-looking
statements as there are important factors that could cause actual
results to differ materially from those in forward-looking statements,
many of which are beyond our control. The Company undertakes no
obligation to publicly update forward-looking statements, whether as a
result of new information, future events, or otherwise. Investors are
referred to the full discussion of risks and uncertainties as included
in the Company's filings with the Securities and Exchange Commission.
Retrophin, Inc.
Chris Cline, CFA, 646-564-3680
Manager,
Investor Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media